Oncogenic miR-9 is a target of erlotinib in NSCLCs

Area of Science:

• Oncology
• Molecular Biology
• Gene Regulation

Background:

• Epidermal growth factor receptor (EGFR)-targeted therapy, like erlotinib, is crucial for non-small cell lung cancer (NSCLC).
• MicroRNAs (miRNAs) are vital in cancer development, but their specific role in EGFR-targeted therapy remains unclear.
• Understanding miRNA involvement can reveal new therapeutic strategies.

Purpose of the Study:

• To investigate the role of miR-9 in NSCLC and its interaction with erlotinib.
• To elucidate the molecular mechanism linking miR-9, FoxO1, and erlotinib's efficacy.
• To explore novel strategies for enhancing EGFR-targeted cancer therapy.

Main Methods:

• Assessed miR-9 expression in NSCLC tissues and cells.
• Utilized overexpression and knockdown techniques for miR-9 and FoxO1 (using adenovirus and siRNA).
• Investigated the direct interaction between miR-9 and FoxO1 mRNA using translation inhibition assays.
• Examined the effect of erlotinib on miR-9 and FoxO1 expression and DNA methylation.

Main Results:

• Erlotinib treatment decreased miR-9 expression in NSCLC cells.
• miR-9 was upregulated in NSCLC tissues and promoted cell growth, counteracting erlotinib's effects.
• miR-9 directly inhibited FoxO1 translation, and FoxO1 overexpression reduced miR-9's pro-growth effects.
• Erlotinib upregulated FoxO1 protein, while miR-9 overexpression diminished this effect.
• Erlotinib suppressed miR-9 transcription, potentially involving DNA methylation.

Conclusions:

• Oncogenic miR-9 promotes NSCLC growth by targeting FoxO1.
• The downregulation of the miR-9/FoxO1 axis contributes to erlotinib's anti-cancer effects.
• Targeting miR-9 regulation could offer novel strategies to improve EGFR-targeted cancer therapy.